Pregabalin controlled-release - Intellipharmaceutics

Drug Profile

Pregabalin controlled-release - Intellipharmaceutics

Alternative Names: Pregabalin extended-release capsules; Pregabalin XR; Pregabalin XR - Intellipharmaceutics; RegabatinXR

Latest Information Update: 06 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intellipharmaceutics International
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Fibromyalgia; Neuropathic pain

Most Recent Events

  • 02 Feb 2017 Pregabalin controlled-release is still in phase I trials for Fibromyalgia and Neuropathic pain in Canada
  • 15 Mar 2016 Biomarkers information updated
  • 09 Oct 2015 Intellipharmaceutics files an IND application with FDA in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top